{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:37:07Z","timestamp":1771925827094,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.vaccine.2010.04.070","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T08:55:38Z","timestamp":1273222538000},"page":"4719-4730","source":"Crossref","is-referenced-by-count":51,"title":["A summary of the post-licensure surveillance initiatives for GARDASIL\/SILGARD\u00ae"],"prefix":"10.1016","volume":"28","author":[{"given":"Paolo","family":"Bonanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cohet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina B.","family":"Latham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul-Henri","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"RR-2","key":"10.1016\/j.vaccine.2010.04.070_bib1","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2010.04.070_bib2","unstructured":"World Health Organization. Meeting of the Immunization Strategic Advisory Group of Experts, November 2008 - conclusions and recommendations. 9-1-2009. Weekly Epidemiological Report No. 1-2, 2009, 84, 1-16. Available at https:\/\/www who int\/wer\/2009\/wer8401_02 pdf 2009 [cited June 2, 2009]."},{"key":"10.1016\/j.vaccine.2010.04.070_bib3","unstructured":"Centers for Disease Control and Prevention. Human papillomavirus (HPV) vaccine post-licensure monitoring and implementation activities centers for disease control and prevention. Available at http:\/\/www cdc gov\/std\/hpv\/HPV-monitoring-plan-10-06-2008 pdf 2009."},{"issue":"19","key":"10.1016\/j.vaccine.2010.04.070_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2010.04.070_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/CDLI.12.8.959-969.2005","article-title":"Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2010.04.070_bib6","unstructured":"International patent numbers WO 2003\/019143 A2, WO 2006\/116276 A2 and WO 2006\/116303 A2. Available at http:\/\/www wipo int\/portal\/index html en 2008."},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.070_bib7","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1101\/gr.3.6.S113","article-title":"Sample preparation and PCR amplification from paraffin-embedded tissues","volume":"3","author":"Greer","year":"1994","journal-title":"PCR Methods Appl"},{"issue":"10","key":"10.1016\/j.vaccine.2010.04.070_bib8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2010.04.070_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"19","key":"10.1016\/j.vaccine.2010.04.070_bib10","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.04.070_bib11","unstructured":"Giuliano A, Palefsky J. 2008 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. \u201cEfficacy of quadrivalent HPV (types 6\/11\/16\/18) vaccine in reducing the incidence of HPV-related genital disease in young men.\u201d [cited July 12, 2009]. Available at http:\/\/www eurogin com\/2008\/EUROGIN2008_LastMinuteAbstracts pdf 2008."},{"key":"10.1016\/j.vaccine.2010.04.070_bib12","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine","author":"Block","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2010.04.070_bib13","unstructured":"Merck & Co., Inc. The Pregnancy Registry for GARDASIL [cited July 12, 2009]. Available at http:\/\/www merckpregnancyregistries com\/gardasil html 2009."},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.070_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/pds.868","article-title":"A five-year evaluation of reports of overdose with indinavir sulfate","volume":"12","author":"Lehman","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2010.04.070_bib15","unstructured":"Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record. Atlanta, GA. Centers for Disease Control and Prevention 1998."},{"key":"10.1016\/j.vaccine.2010.04.070_bib16","unstructured":"Centers for Disease Control and Prevention. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies, Atlanta, GA, version 08\/07. Available at http:\/\/www.cdc.gov\/ncbddd\/BD\/documents\/MACDPcode.pdf. Accessed February 2, 2009. Centers for Disease Control and Prevention - MMWR Morbidity and Mortality Weekly Report 2009."},{"key":"10.1016\/j.vaccine.2010.04.070_bib17","series-title":"Foundations of epidemiology","author":"Lilienfeld","year":"1994"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.070_bib18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6\/11\/16\/18 vaccine","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2010.04.070_bib19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.vaccine.2010.04.070_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1098\/rsif.2007.0236","article-title":"Vaccine-induced pathogen strain replacement: what are the mechanisms?","volume":"5","author":"Martcheva","year":"2008","journal-title":"J R Soc Interface"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.070_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.virusres.2007.12.020","article-title":"HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy","volume":"133","author":"Capra","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2010.04.070_bib22","unstructured":"Belgian Cancer Registry. Annual statistics since 1999: 2003-F-BEL-Lft [online]. Available from URL: http:\/\/www.registreducancer.org. Belgian Cancer Registry Annual statistics since 1999: 2003-F-BEL-Lft [online] Available from URL: http:\/\/www registreducancer org [Accessed February 4, 2010]."},{"issue":"15","key":"10.1016\/j.vaccine.2010.04.070_bib23","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ejca.2009.07.019","article-title":"HPV infection in Europe","volume":"45","author":"De Vuyst","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.vaccine.2010.04.070_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","article-title":"Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions","volume":"26","author":"Siegrist","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"33","key":"10.1016\/j.vaccine.2010.04.070_bib25","first-page":"1545","article-title":"EVE, a regional campaign for the screening of cervical cancer. Organization, 7-years results and perspectives","volume":"32","author":"Fender","year":"2003","journal-title":"Presse Med"},{"issue":"33","key":"10.1016\/j.vaccine.2010.04.070_bib26","first-page":"1545","article-title":"Membres du bureau de l\u2019Association EVE. [EVE, a regional campaign for the screening ofcervical cancer. Organization, 7-years results and perspectives]","volume":"32","author":"Fender","year":"2003","journal-title":"Presse Med."},{"issue":"7","key":"10.1016\/j.vaccine.2010.04.070_bib27","first-page":"683","article-title":"Can we and must we organize cervical cancer screening in France? Results of the pilot project \u201cEVE\u201d in the department of Bas-Rhin","volume":"27","author":"Fender","year":"1998","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.070_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/ijc.24712","article-title":"Attitudes to HPV vaccination among parents of children aged 12\u201315 years\u2014a population-based survey in Sweden","volume":"126","author":"Dahlstrom","year":"2010","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2010.04.070_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2010.04.070_bib30","unstructured":"Public Health Agency of Canada, Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33(ACS-2):1\u201331."},{"key":"10.1016\/j.vaccine.2010.04.070_bib31","unstructured":"Flaherty JM. The Budget Plan 2007. Aspite to a stronger, safer, better Canada. http:\/\/www budget gc ca\/2007\/pdf\/speeche pdf March 19, 2007 [cited August 19, 2009]."},{"key":"10.1016\/j.vaccine.2010.04.070_bib32","unstructured":"Colucci R, Hryniuk W, Savage C. Report card on cancer in Canada, 2008. HPV vaccination programs in Canada: are we hitting the mark? http:\/\/www canceradvocacy ca\/reportcard\/2008\/reportcard-2008 pdf 2009 [cited August 19, 2009]."},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.070_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/sti.2008.030999","article-title":"Epidemiology and costs associated with genital warts in Canada","volume":"85","author":"Marra","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.070_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/OLQ.0b013e318198de8c","article-title":"Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada","volume":"36","author":"Kliewer","year":"2009","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2010.04.070_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ypmed.2008.12.022","article-title":"Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination","volume":"48","author":"Howlett","year":"2009","journal-title":"Prev Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10006067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10006067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T11:26:34Z","timestamp":1591269994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10006067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":35,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0264410X10006067"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.04.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}